Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences - 1 Jan 2006

Xie Hanjing, Griskevicius Laimonas, Ståhle Lars, Hassan Zuzana, Yasar Umit, Rane Anders, Broberg Ulrika, Kimby Eva, Hassan Moustapha

Abstract excerpt

PURPOSE: A high degree of interindividual variation in cyclophosphamide (CPA) pharmacokinetics was reported in certain cancer patient groups. To better understand the mechanisms underlying the variation in CPA metabolism, we have investigated the pharmacokinetics of CPA and its active metabolite 4-hydroxycyclophosphamide (4-OH-CPA) in patients with hematological tumors. The pharmacokinetics of CPA and its active...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bilirubin

Share to Cyclophosphamide

Share to Cytochrome P-450 CYP2B6

Share to Hematologic Neoplasms

Share to Oxidoreductases, N-Demethylating

Share to Pharmacogenetics

Source

Identifiers

PMID: 16183265
DOI: 10.1016/j.ejps.2005.08.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.PMID 16183265Read ↗

Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.Semantic proximity Read ↗

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesSemantic proximity Read ↗

Cyclophosphamide pharmacogenomics and their effect on its bioactivation and pharmacokineticsSemantic proximity Read ↗

Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19.Semantic proximity Read ↗

Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.Semantic proximity Read ↗

Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.Semantic proximity Read ↗

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastomaSemantic proximity Read ↗

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.Semantic proximity Read ↗

Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy.Semantic proximity Read ↗

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Semantic proximity Read ↗

Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer TherapySemantic proximity Read ↗

Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.